Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Jazz Pharmaceuticals PLC    JAZZ   IE00B4Q5ZN47

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Jazz Pharmaceuticals PLC
Operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products.

It has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.

Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd on January 18, 2012 and is headquartered in Dublin, Ireland.

Number of employees : 910 persons.
Sales per Businesses
20142015Delta
USD (in Million)%USD (in Million)%
Pharmaceutical Products1,173100%1,325100% +12.95%
Sales per Regions
20142015Delta
USD (in Million)%USD (in Million)%
United States1,00785.9%1,19390% +18.41%
Europe126.7210.8%103.617.8% -18.23%
All Other38.763.3%28.312.1% -26.97%
Managers
NameAgeSinceTitle
Bruce C. Cozadd, MBA532012Chairman & Chief Executive Officer
Russell J. Cox542012Chief Operating Officer & Executive Vice President
Matthew P. Young, MBA482013Chief Financial Officer & Executive Vice President
Karen L. Smith MD, PhD492015Chief Medical Officer, Global Head-R&D
Paul L. Berns502010Independent Class II Director
Patrick G. Enright, MBA552012Independent Director
Seamus C. Mulligan562012Independent Director
Ken W. O'Keefe, MBA502012Independent Director
Rick E. Winningham, MBA572012Lead Independent Director
Catherine Angell Sohn, PhD632012Independent Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 59,892,335 58,494,768 97.7% 0 0.0% 97.7%
Shareholders
NameEquities%
Fidelity Management & Research Co. 8,703,053 14.5%
Putnam Investment Management LLC 7,564,438 12.6%
The Vanguard Group, Inc. 4,289,739 7.16%
BlackRock Fund Advisors 2,109,973 3.52%
FIL Investment Advisors (UK) Ltd 1,798,486 3.00%
Westfield Capital Management Co. LP 1,637,937 2.73%
Cadian Capital Management LP 1,311,292 2.19%
Partner Fund Management LP 1,182,693 1.97%
Seamus C. Mulligan 1,048,008 1.75%
Janus Capital Management LLC 977,224 1.63%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Specialty & Advanced Pharmaceuticals
Advertisement
Sector Specialty & Advanced Pharmaceuticals
1st jan.Capitalization (M$)
JAZZ PHARMACEUTICALS P..6.00%6 922
ABBVIE INC-1.21%100 529
MERCK KGAA3.08%14 107
KYOWA HAKKO KIRIN CO L..-2.78%8 000
MALLINCKRODT PLC-0.80%5 232
ZHANGZHOU PIENTZEHUANG..-0.68%3 983
INDIVIOR PLC2.70%2 626
YUHAN CORPORATION--.--%2 022
MAYNE PHARMA GROUP LTD-6.69%1 416
SUPERNUS PHARMACEUTICA..-5.74%1 178
ADVANCED ACCELERATOR A..--.--%1 135
THERAPEUTICSMD INC0.87%1 128
KNIGHT THERAPEUTICS IN..-4.11%1 120
EAGLE PHARMACEUTICALS ..-12.05%1 077
REPLIGEN CORPORATION-3.60%1 005
AIMMUNE THERAPEUTICS I..-4.84%974
LG LIFE SCIENCES, LTD--.--%968
NICHI-IKO PHARMACEUTIC..1.43%908
STALLERGENES GREER13.92%744
DONG-A ST CO LTD--.--%684
RECIPHARM AB (PUBL)1.24%655
Sector Specialty & Advanced Pharmaceuticals
Jazz Pharmaceuticals PLC : Connections
Vascular Cures
Beecken Petty O'Keefe & Co. LP
CHD Bioscience, Inc.
Adapt Pharma Ltd.
Ariel Pharmaceuticals, Inc.
Longitude Capital Management Co. LLC
World Affairs Council of Philadelphia
Circ Pharma Ltd.
Pharmaceutical Research & Manufacturers of America
SutroVax, Inc.
Sohn Health Strategies LLC
Orbus Therapeutics, Inc.
Nueva School
Aptinyx, Inc.
InfaCare Pharmaceutical Corp.
Raven Biotechnologies, Inc.
University of the Sciences in Philadelphia
Company contact information
Jazz Pharmaceuticals Plc
Connaught House
One Burlington Road
4th Floor
Dublin 4

Phone : +353.1.634.7800
Fax : +353.1.634.7850
Web : www.jazzpharma.com
© 2017 People , Fundamentals and Ownership